Skip to main content

Table 3 Pharmacological characterization of spotted gar fabp1 promoter PPRE mutants

From: Subfunctionalization of peroxisome proliferator response elements accounts for retention of duplicated fabp1 genes in zebrafish

 

WY14643

 

Upward Slope

Downward Slope

 

No mutation

ΔPPRE-1

ΔPPRE-2

No mutation

ΔPPRE-1

ΔPPRE-2

E max (RLU)

101 ± 2.56

70.6 ± 2.17*

102 ± 8.65

-

-

-

E min (RLU)

1.32 ± 2.91

–1.64 ± 3.08

–17.4 ± 18.2

27.6 ± 4.76**

-

-

EC50 (μM)

0.013 (0.004–0.023)

0.045 (0.032–0.064)*

0.028 (0.008–0.098)

0.38 (0.20–0.41)**

-

-

 

Rosiglitazone

 

Upward Slope

Downward Slope

 

No mutation

ΔPPRE-1

ΔPPRE-2

No mutation

ΔPPRE-1

ΔPPRE-2

E max (RLU)

64.9 ± 2.34

61.9 ± 6.66

62.1 ± 5.07

-

-

-

E min (RLU)

−7.47 ± 3.79

1.17 ± 0.05

2.94 ± 4.03

-

-

-

EC50 (μM)

0.008 (0.003–0.019)

0.003 (0.001–1.34)

0.18 (0.08–0.36)*

-

-

-

  1. Data derived from Fig. 6 presented as the mean ± SEM or 95 % confidence intervals (brackets)
  2. *P < 0.05 compared to agonist treatment alone within the upward slope
  3. **P < 0.05 compared to matched treatment between upward and downward slopes, as determined via two-way ANOVA followed by Bonferroni’s post-hoc analysis for E max, E min, or by non-overlapping confidence intervals (EC50). n = 3